GET DAILY SIGNALSJohnson & Johnson (JNJ) Advances +7.7% Following Robust Third-Quarter Results
Key Takeaways
- Johnson & Johnson (JNJ) shares advanced roughly 7.7% over the trailing 30 days, climbing from about $256 to approximately $276 and trading near 52-week highs.
- The move was supported by third-quarter 2026 results that beat consensus estimates, with adjusted EPS of $2.59 and revenue near $25.4 billion, up about 6% year over year.
- Oncology remains the company's primary growth engine, led by Darzalex, Carvykti, Tecvayli, Rybrevant, Lazcluze, and Erleada, which helped offset Stelara's biosimilar-driven decline.
- Reported net income was sharply reduced by roughly $7 billion in one-time charges, primarily tied to the proposed $5.5 billion ovarian talc settlement, plus costs from the Firefly Bio acquisition and Sail Biomedicines collaboration.
- MedTech growth lagged at about 2.5%, pressured by electrophysiology competition and China pricing, though the OTTAVA robotic surgery authorization provides a new platform.
- Johnson & Johnson remains a Dividend King, having increased its dividend for 64 consecutive years, and declared a $1.34 per-share quarterly dividend in October 2026.
Recent Price Action and Market Context
Johnson & Johnson shares have moved steadily higher over the past 30 days, posting a gain of roughly 7.7% from a close near $256.48 in early October to around $276 by early November. The stock has been holding near multi-year and 52-week highs, which points to steady investor confidence in the shift toward higher-growth areas in oncology and immunology. I checked comparable moves in the sector using Tickeron’s AI Screener to see how JNJ stacks up against peers.
Broader healthcare sentiment has stayed constructive, with large-cap names offering defensive cash flows, reliable dividends, and clear pipelines attracting attention. JNJ raising full-year guidance despite a large litigation charge has reinforced its image as a steady, diversified healthcare operator.
Business Overview and Competitive Strengths
JNJ operates across Innovative Medicine and MedTech. The first covers oncology, immunology, neuroscience, cardiovascular, and infectious disease therapies, while MedTech includes surgical devices, orthopaedics, vision care, and cardiovascular technologies. Its strengths lie in a diversified revenue base, a deep late-stage pipeline, a long innovation record, and strong free cash flow that has supported 64 straight years of dividend increases. Oncology stands out as the main growth driver, with management aiming to become the top oncology company by decade’s end.
Key Developments Behind the Recent Move
Third-quarter 2026 results, released in mid-October, showed adjusted earnings and sales above expectations, prompting management to lift full-year guidance. Oncology products such as Darzalex, Carvykti, Tecvayli, and the Rybrevant/Lazcluze combination drove the gains and helped counter the drop in Stelara sales from biosimilar competition. Reported profit took a hit from about $7 billion in one-time charges, mostly linked to the proposed $5.5 billion ovarian talc settlement. That settlement still needs at least 95% claimant participation to go through. Additional costs came from the Firefly Bio acquisition and Sail Biomedicines collaboration.
MedTech grew more modestly at about 2.5%, supported by cardiovascular electrophysiology, contact lenses, and orthopaedic trauma, but faced pressure from China pricing and electrophysiology competition. A notable positive was market authorization for the OTTAVA robotic surgery system. In October 2026 the company also declared its quarterly dividend of $1.34 per share, continuing its long record of returning capital to shareholders. I reviewed the earnings details further with Tickeron’s AI Trend Prediction Engine for added context on the numbers.
Looking Ahead Into 2027
Several items will shape the outlook for JNJ through the rest of 2026 and into 2027. The December enterprise business review should give more color on 2027 plans, including how the company will handle the roughly $1.36 per-share earnings impact from recent deals. Investors will track the final participation rate on the talc settlement and watch for potential U.S. approval of Rybrevant FASPRO in advanced head and neck cancer before year-end. MedTech sales growth in the fourth-quarter report will also draw scrutiny after the segment missed internal targets. Risks remain around drug pricing reform, competition in key therapeutic areas, and the planned orthopaedics separation. Sustaining oncology momentum while addressing MedTech softness and litigation overhang will be key.
Incorporating Tickeron AI Tools Into My Research
I often turn to Tickeron’s AI Trading Bots when evaluating systematic strategies that align with a stock’s momentum profile. The platform hosts hundreds of AI-driven bots across thousands of tickers, and the trending section highlights those with strong recent performance and relevance. Reviewing these can offer a useful complement to traditional fundamental analysis without replacing it. AI Trading Bots
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
JNJ in upward trend: 10-day moving average crossed above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Indicator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 18 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.360). P/E Ratio (31.640) is within average values for comparable stocks, (21.695). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement